Neurocrine Biosciences | NBIX - Current Assets


Neurocrine Biosciences reported $1.64B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Exelixis USD 1.21B 234.65M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Pfizer USD 42.82B 76M Mar/2026
Prothena USD 339.2M 24.01M Mar/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Repligen USD 1.2B 39.19M Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Teva Pharmaceutical Industries USD 13.76B 50M Jun/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026